IP Library Patent Application 16677214
Patent Application
App. No. 16/677,214

CYSTEINE COMPOSITION AND INJECTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/677,214
Abstract

Cysteine compositions comprising less than about 400 μg/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 μg/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.

Claims (33)

1 . A solution of cysteine comprising a pharmaceutically acceptable solvent, about 40 mg/mL to about 60 mg/mL of cysteine hydrochloride, less than about 200 μg/L of aluminum, and a pH from about 1.0 to about 1.5, wherein the solution is devoid of visible particulate matter and is suitable for use as an additive in a total parenteral nutrition formulation for a neonate or an infant.

2 . The solution of claim 1 , which comprises from 42.5 mg/mL to 57.5 mg/mL of cysteine hydrochloride monohydrate.

3 . The solution of claim 1 which comprises about 50 mg/mL of cysteine hydrochloride monohydrate.

4 . The solution of claim 1 , which comprises less than about 145 μg/L of aluminum.

5 . The solution of claim 4 , which comprises less than about 100 μg/L of aluminum.

6 . The solution of claim 5 , which comprises less than about 30 μg/L of aluminum.

7 . The solution of claim 6 , which comprises less than about 10 μg/L of aluminum.

8 . The solution of claim 1 , which comprises from about 1 μg/L to about 145 μg/L of aluminum.

9 . The solution of claim 1 , which comprises from about 0 μg/L to about 100 μg/L of aluminum.

10 . The solution of claim 1 , wherein the pH is from about 1.0 to about 1.3.

11 . The solution of claim 1 , which has a dissolved oxygen content of less than 2 mg/L.

12 . (canceled)

13 . The solution of claim 1 , which has a cystine content of less than about 1% by weight of the total cysteine present in the solution.

14 . The solution of claim 1 , wherein the pharmaceutically acceptable solvent is water.

15 . A sterile solution of about 50 mg/mL of cysteine hydrochloride in water for injection, wherein the sterile solution has a pH from about 1.0 to about 1.5 and an aluminum content of less than about 145 μg/L, wherein the sterile solution is provided in a silica-lined glass vial and is suitable for use as an additive in a total parenteral nutrition formulation for a neonate or an infant.

16 . The sterile solution of claim 15 , wherein the pH is from about 1.0 to about 1.3.

17 . (canceled)

18 . The sterile solution of claim 15 , wherein the aluminum content is less than about 100 μg/L.

19 . The sterile solution of claim 18 , wherein the aluminum content is less than about 30 μg/L.

20 .- 27 . (canceled)

28 . The sterile solution of claim 15 , wherein the aluminum content is from about 0 μg/L to about 30 μg/L.

29 . (canceled)

30 . The sterile solution of claim 15 , which has a dissolved oxygen content of less than 2 mg/L.

31 . The sterile solution of claim 15 , which is devoid of visible particulate matter when stored for one month at 25° C. and 60% relative humidity.

32 . The sterile solution of claim 31 , which is devoid of visible particulate matter when stored for six months at 25° C. and 60% relative humidity.

33 . The sterile solution of claim 32 , which is devoid of visible particulate matter when stored for nine months at 25° C. and 60% relative humidity

34 . The sterile solution of claim 33 , which is devoid of visible particulate matter when stored for 12 months at 25° C. and 60% relative humidity.

35 . The sterile solution of claim 34 , which is devoid of visible particulate matter when stored for 18 months at 25° C. and 60% relative humidity.

36 . The sterile solution of claim 35 , which is devoid of visible particulate matter when stored for 24 months at 25° C. and 60% relative humidity.

37 . The sterile solution of claim 15 , wherein the aluminum content is less than about 145 μg/L when stored for six months at 25° C. and 60% relative humidity.

38 . The sterile solution of claim 37 , wherein the aluminum content is less than about 145 μg/L when stored for 12 months at 25° C. and 60% relative humidity.

39 . The sterile solution of claim 38 , wherein the aluminum content is less than about 145 μg/L when stored for 24 months at 25° C. and 60% relative humidity.

40 . The sterile solution of claim 15 , wherein the silica-lined glass vial is filled and sealed under flow of an inert gas.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2021
From: AVADEL LEGACY PHARMACEUTICALS, LLC
To: EXELA STERILE MEDICINES LLC
Reel/Frame 056743/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2020
From: AVADEL LEGACY PHARMACEUTICALS, LLC
To: EXELA STERILE MEDICINES LLC
Reel/Frame 053101/0505 →
SECURITY INTEREST Recorded Jul 1, 2020
From: EXELA STERILE MEDICINES LLC
To: AVADEL LEGACY PHARMACEUTICALS, LLC
Reel/Frame 053101/0559 →
SECURITY INTEREST Recorded Jul 1, 2020
From: EXELA STERILE MEDICINES LLC
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P.
Reel/Frame 053101/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2020
From: FLAMEL IRELAND LIMITED
To: AVADEL LEGACY PHARMACEUTICALS, LLC
Reel/Frame 051666/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: SUTTERER, ANGELA; SIMPSON, JILL; POULIQUEN, GAUTHIER; CONSTANCIS, ALAIN; DANNER, PIERRE
To: FLAMEL IRELAND LIMITED
Reel/Frame 050992/0249 →